Table of Content

1          Target Background

2          Target Antigen Expression Profile

3          Preclinical Proof-of-Concept

4          Clinical Experience with CLDN6-Targeted Drug Modalities

5          Clinical Indications & Patient Populations

6          Competitive Landscape & Drug Modalities

7          Drug & Cell Therapy Candidate Profiles

7.1       CAR T-Cells

7.2       Antibody-Drug Conjugates (ADC)

7.3       T-Cell Redirecting Bispecific Antibodies

7.4       T-Cell Activating Bispecific Antibodies

7.5       Failed Drug Modalities

8          Company Profiles   

9          References